drugset
drugset / Trial / NCT02206659

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

NCT02206659 ↗

Phase 3 Completed 20 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension

Timeline

Start
2000-08
Primary completion
2001-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Telmisartan Other / unclassified 40 mg —

Indications

hypertensive disorder